Enzon drug delivery, infectious, cancer news

Knott Partners, which owns about 4% of Enzon, sent a letter to CEO Jeffery Buchalter and the board suggesting immediate action, including a share buyback plan; an auction for the entire company

Read the full 323 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE